Beam Therapeutics Inc
Price
OptionsOpen the Sheet →FilingsNewest: 10-Q, Quarterly reportAug 4 →InsidersNo open-market buys. 7 insiders sold $6.3M, 20 of 21 sales on a 10b5-1 plan.→HoldersFMR 12.2%Farallon 9.9%ARK 9.9%→PeersClosest companies: EDIT, MGX, DTIL→
From the filings
Figures
- Revenue
- $156.0Mlast 12 months
- Net income
- −$85.4Mlast 12 months
- Operating cash flow
- −$369.7Mlast 12 months
- Cash and equivalents
- $219.8Mat the last balance sheet
- Total debt
- $100.3Mat the last balance sheet
- Shares outstanding
- 103.3M shareson issue